Hendrik Peter Scholl, the Chief Medical Officer of $BLTE, sold 540 shares of the company on 06-16-2026 for an estimated $75,914. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.9% of their shares of this class of stock. Following this trade, they now own 28,482 shares of this class of $BLTE stock.
$BLTE Insider Trading Activity
$BLTE insiders have traded $BLTE stock on the open market 110 times in the past 6 months. Of those trades, 0 have been purchases and 110 have been sales.
Here’s a breakdown of recent trading of $BLTE stock by insiders over the last 6 months:
- NATHAN L. MATA (Chief Scientific Officer) has made 0 purchases and 93 sales selling 15,000 shares for an estimated $2,411,919.
- YU-HSIN LIN (Chief Executive Officer) has made 0 purchases and 4 sales selling 9,200 shares for an estimated $1,669,338.
- HENDRIK PETER SCHOLL (Chief Medical Officer) has made 0 purchases and 8 sales selling 10,000 shares for an estimated $1,405,729.
- HAO-YUAN CHUANG (Chief Financial Officer) has made 0 purchases and 4 sales selling 6,200 shares for an estimated $1,125,303.
- WAN-SHAN CHEN sold 1,100 shares for an estimated $198,473
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BLTE Hedge Fund Activity
We have seen 59 institutional investors add shares of $BLTE stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 1,114,784 shares (+inf%) to their portfolio in Q1 2026, for an estimated $177,741,160
- UBS GROUP AG added 639,607 shares (+496.8%) to their portfolio in Q1 2026, for an estimated $101,978,940
- RA CAPITAL MANAGEMENT, L.P. removed 432,484 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $68,955,248
- HOLOCENE ADVISORS, LP added 410,428 shares (+488.2%) to their portfolio in Q1 2026, for an estimated $65,438,640
- PERCEPTIVE ADVISORS LLC added 364,451 shares (+732.0%) to their portfolio in Q4 2025, for an estimated $58,297,581
- VESTAL POINT CAPITAL, LP removed 312,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $49,987,500
- POINT72 ASSET MANAGEMENT, L.P. removed 284,437 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $45,350,635
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BLTE Analyst Ratings
Wall Street analysts have issued reports on $BLTE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
To track analyst ratings and price targets for $BLTE, check out Quiver Quantitative's $BLTE forecast page.
$BLTE Price Targets
Multiple analysts have issued price targets for $BLTE recently. We have seen 5 analysts offer price targets for $BLTE in the last 6 months, with a median target of $201.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $200.0 on 06/15/2026
- Graig Suvannavejh from Mizuho set a target price of $215.0 on 05/26/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $266.0 on 03/03/2026
- Judah Frommer from Morgan Stanley set a target price of $201.0 on 03/03/2026
- Tazeen Ahmad from B of A Securities set a target price of $195.0 on 01/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
